Abstract:Influenza vaccines, which are recommended by the World Health Organization (WHO), are the most effective preventive measure against influenza virus infection. Madin–Darby canine kidney (MDCK) cell culture is an emerging technology used to produce influenza vaccines. One challenge when purifying influenza vaccines using this cell culture system is to efficiently remove impurities, especially host cell double-stranded DNA (dsDNA) and host cell proteins (HCPs), for safety assurance. In this study, we optimized ion-exchange chromatography methods to harvest influenza viruses from an MDCK cell culture broth, the first step in influenza vaccine purification. Bind/elute was chosen as the mode of operation for simplicity. The anion-exchange Q chromatography method was able to efficiently remove dsDNA and HCPs, but the recovery rate for influenza viruses was low. However, the cation-exchange SP process was able to simultaneously achieve high dsDNA and HCP removal and high influenza virus recovery. For the SP process to work, the clarified cell culture broth needed to be diluted to reduce its ionic strength, and the optimal dilution rate was determined to be 1:2 with purified water. The SP process yielded a virus recovery rate exceeding 90%, as measured using a hemagglutination units (HAUs) assay, with removal efficiencies over 97% for HCPs and over 99% for dsDNA. Furthermore, the general applicability of the SP chromatography method was demonstrated with seven strains of influenza viruses recommended for seasonal influenza vaccine production, including H1N1, H3N2, B (Victoria), and B (Yamagata) strains, indicating that the SP process could be utilized as a platform process. The SP process developed in this study showed four advantages: (1) simple operation, (2) a high recovery rate for influenza viruses, (3) a high removal rate for major impurities, and (4) general applicability.

[Preparation and Identification of High Immunogenic A/PR/8/34 Maternal Strain HA Protein for Influenza Virus Classical Reassortment].

Preparation of Maternal Strain X-157 HA Antiserum for Influenza Virus

Identification and Analysis of B Cell Epitopes of Hemagglutinin of H1N1 Influenza Virus.

Establishment of seasonal influenza vaccine strain development platform

Preparation of monoclonal antibodies against Yamagata-lineage influenza B virus hemagglutinin protein and establishment of a dual antibody sandwich ELISA detection method

Generation and Characterization of Monoclonal Antibodies Against the Hemagglutinin of H3N2 Influenza A Viruses.

Preparation and Antigenic Site Identification of Monoclonal Antibodies against PB1 Protein of H9N2 Subtype AIV

Preclinical Evaluation of the Safety and Pathogenicity of a Live Attenuated Recombinant Influenza A/H7N9 Seed Strain and Corresponding MF59-adjuvanted Split Vaccine

A Single-Step Method for Harvesting Influenza Viral Particles from MDCK Cell Culture Supernatant with High Yield and Effective Impurity Removal

Immunological study of HA1 domain of hemagglutinin of influenza H5N1 virus

Prokaryotic Expression and Purification of HA1 and HA2 Polypeptides for Serological Analysis of the 2009 Pandemic H1N1 Influenza Virus.

Preparation and evaluation of a novel, live, attenuated influenza H1N1 vaccine strain produced by a modified classical reassortment method

Identification of Linear Peptide Immunogens with Verified Broad-spectrum Immunogenicity from the Conserved Regions within the Hemagglutinin Stem Domain of H1N1 Influenza Virus

Production of Influenza Virus HA1 Harboring Native-Like Epitopes by Pichia Pastoris.

Construction and Comparison of Different Source Neuraminidase Candidate Vaccine Strains for Human Infection with Eurasian Avian-Like Influenza H1N1 Virus.

Application of Deglycosylation and Electrophoresis to the Quantification of Influenza Viral Hemagglutinins Facilitating the Production of 2009 Pandemic Influenza (H1N1) Vaccines at Multiple Manufacturing Sites in China

Identification of key antigenic sites in hemagglutinin of H10N3 avian influenza virus

Development of high-replicated canine influenza virus-PR8 reassortant virus

Antigenic analysis of the influenza B virus hemagglutinin protein

Formulation development of a plant-derived H1N1 influenza vaccine containing purified recombinant hemagglutinin antigen

Generation of cold-adapted, attenuated reassortant human influenza A virus with eight-plasmid system